RNA therapeutics have emerged as one of the most promising new classes of medicines. Eight small interfering RNA (siRNA) ...
RNA therapeutics have emerged as one of the most promising new classes of medicines. Eight small interfering RNA (siRNA) ...
Since its discovery in 1998 and winning the Nobel Prize in 2006, ribonucleic acid (RNA) interference has become an invaluable tool for drugmakers to silence disease-causing genes. Nearly three decades ...
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and ...
A Novel, Double-stranded Small Interfering RNA Therapeutic Designed to Silence Apolipoprotein C-III in Familial Chylomicronemia Syndrome Home / publications / supplement / ...
The natural RNAi mechanism can be directed by either short interfering RNA (siRNA) or microRNA (miRNA). 1 There are four key steps in the RNAi pathway. When miRNA acts as the guide for RNAi, only a ...
Lipoprotein(a) is similar to LDL cholesterol but contains apolipoprotein(a). A trial tested the effects of an oligonucleotide drug targeting apo(a) mRNA on lipoprotein(a) concentrations in patients ...
Gene knockdown is a common method for studying gene function by reducing messenger ribonucleic acid (mRNA) levels without altering the deoxyribonucleic acid (DNA). Among the available techniques, RNA ...
AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license option ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results